Comparison of Anticancer Effects of Carbamazepine and Valproic Acid

被引:19
作者
Akbarzadeh, Ladan [1 ]
Zanjani, Taraneh Moini [1 ]
Sabetkasaei, Masoumeh [1 ]
机构
[1] Shahid Beheshti Univ, Dept Pharmacol, Tehran, Iran
关键词
Histone Deacetylase Inhibitor; beta-Catenin; VEGF; HISTONE DEACETYLASE INHIBITORS; GENE-EXPRESSION; CANCER; GROWTH; MECHANISMS;
D O I
10.5812/ircmj.37230
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Valproic acid (VPA) andcarbamazepine (CBZ), two widely used antiepileptic drugs, have recently been found to inhibit histone deacetylases (HDAC). HDAC inhibitors (HDACIs) have various effects on cancer cells. Objectives: The aim of this study was to compare the anticancer activity of these drugs on SW480 colon cancer cell lines. Methods: In the present experimental study, implemented during 2014 - 2015 in Iran, after incubation of cells into 96-well plates with 5,500 cells/well, the tested drugs were added, and cytotoxic effects were assessed by MTT. Moreover, after incubation of 8 x 10(6) cells in 75 cm(2) flasks to obtain beta-catenin levels and 106 cells in a six-well plate to obtain vascular endothelial growth factor (VEGF) levels, these levels were estimated using enzyme-linked immunosorbent assay (ELISA) analysis. Results: Through MTT assay, we found that the inhibitory concentration of 50% (IC50) values for VPA and CBZ were 2.5 mM and 5 mu M, respectively in comparison to controls in terms of total concentration and times evaluated (P < 0.0001). We also found that treatments with these drugs decreased levels of beta-catenin (P < 0.0001) and VEGF (P < 0.0001) significantly more than controls. Conclusions: VPA and CBZ treatments caused a decrease in beta-Catenin and VEGF levels in SW480 colon cancer cell lines. These results suggest that CBZ can be considered a potential antitumor drug with potencies different from VPA.
引用
收藏
页数:7
相关论文
共 30 条
[1]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[2]   Carbamazepine is an inhibitor of histone deacetylases [J].
Beutler, AS ;
Li, SD ;
Nicol, R ;
Walsh, MJ .
LIFE SCIENCES, 2005, 76 (26) :3107-3115
[3]   Anti-tumor mechanisms of valproate: A novel role for an old drug [J].
Blaheta, RA ;
Cinatl, J .
MEDICINAL RESEARCH REVIEWS, 2002, 22 (05) :492-511
[4]   Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies [J].
Blaheta, RA ;
Michaelis, M ;
Driever, PH ;
Cinatl, J .
MEDICINAL RESEARCH REVIEWS, 2005, 25 (04) :383-397
[5]   Wnt/β-catenin signaling in development and disease [J].
Clevers, Hans .
CELL, 2006, 127 (03) :469-480
[6]   Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma [J].
de Ruijter, AJM ;
Meinsma, RJ ;
Bosma, P ;
Kemp, S ;
Caron, HN ;
van Kuilenburg, ABP .
EXPERIMENTAL CELL RESEARCH, 2005, 309 (02) :451-467
[7]   Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling [J].
Deroanne, CF ;
Bonjean, K ;
Servotte, S ;
Devy, L ;
Colige, A ;
Clausse, N ;
Blacher, S ;
Verdin, E ;
Foidart, JM ;
Nusgens, BV ;
Castronovo, V .
ONCOGENE, 2002, 21 (03) :427-436
[8]  
Glaser KB, 2003, CANC THER, V2, P151
[9]   Histone deacetylases and cancer [J].
Glozak, M. A. ;
Seto, E. .
ONCOGENE, 2007, 26 (37) :5420-5432
[10]   Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells [J].
Göttlicher, M ;
Minucci, S ;
Zhu, P ;
Krämer, OH ;
Schimpf, A ;
Giavara, S ;
Sleeman, JP ;
Lo Coco, F ;
Nervi, C ;
Pelicci, PG ;
Heinzel, T .
EMBO JOURNAL, 2001, 20 (24) :6969-6978